As of November 10, 2026, 4 holders' latest Schedule 13D or 13G filings report owning 5% or more of Veraxa Biotech Holding AG f/k/a Voyager Acquisition Corp. The largest reported stake is Deck David Lukas', at 18%. 5 filings are on record since June 15, 2026 (Schedule 13D, June 16, 2026).
Who owns Veraxa Biotech Holding AG?
Sell to companies like Veraxa Biotech Holding AG f/k/a Voyager Acquisition Corp? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: AQR Capital Management, LLC · Sole voting: 0 · Shared voting: 658,138 · Sole dispositive: 0 · Shared dispositive: 658,138 · SCHEDULE 13G/A, 2026-08-13
- · Reporting person: Deck David Lukas · Sole voting: 25,502,836 · Shared voting: 0 · Sole dispositive: 25,502,836 · Shared dispositive: 0 · SCHEDULE 13D, 2026-06-16
- · Reporting person: European Molecular Biology Laboratory · Sole voting: 0 · Shared voting: 22,891,235 · Sole dispositive: 0 · Shared dispositive: 22,891,235 · SCHEDULE 13D, 2026-06-16
- · Reporting person: Xlife Sciences AG · Sole voting: 23,029,967 · Shared voting: 0 · Sole dispositive: 23,029,967 · Shared dispositive: 0 · SCHEDULE 13D, 2026-06-15
- · Reporting person: Schoeni Gilbert Edgar · Sole voting: 22,539,749 · Shared voting: 0 · Sole dispositive: 22,539,749 · Shared dispositive: 0 · SCHEDULE 13D, 2026-06-15
Veraxa Biotech Holding AG f/k/a Voyager Acquisition Corp has 5 Schedule 13D or 13G filings on record since 2026-06-15. 4 holders' latest filing reports 5% or more of ordinary shares, par value chf 100/11,325 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| 18% | 25,502,836 | SCHEDULE 13D, 2026-06-16 | 2026-06-10 | |
| Xlife Sciences AG | 16.3% | 23,029,967 | SCHEDULE 13D, 2026-06-15 | 2026-06-10 |
| 16.2% | 22,891,235 | SCHEDULE 13D, 2026-06-16 | 2026-06-10 | |
| 15.9% | 22,539,749 | SCHEDULE 13D, 2026-06-15 | 2026-06-10 | |
| AQR Capital Management, LLC | 0.46% | 658,138 | SCHEDULE 13G/A, 2026-08-13 | 2026-06-30 |
Holding shares or following this stake? See who's behind Veraxa Biotech Holding AG f/k/a Voyager Acquisition Corp and the warning signs.
Free to see. No signup.
Keep reading
More on Veraxa Biotech Holding AG f/k/a Voyager Acquisition Corp and the records around it.
Veraxa Biotech Holding AG f/k/a Voyager Acquisition Corp elsewhere on the record
Companies that share a holder
- AQR Capital Management, LLC also filed stake reports on 190 other companies: Bold Eagle Acquisition Corp. (Nov 2026), Centurion Acquisition Corp. (Aug 2026), FG Merger II Corp. n/k/a BOXABL Inc. (Aug 2026)
Watch Veraxa Biotech Holding AG f/k/a Voyager Acquisition Corp
Get an email when Veraxa Biotech Holding AG f/k/a Voyager Acquisition Corp files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Veraxa Biotech Holding AG f/k/a Voyager Acquisition Corp?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Veraxa Biotech Holding AG f/k/a Voyager Acquisition Corp: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Veraxa Biotech Holding AG f/k/a Voyager Acquisition Corp covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
5 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Deck David Lukas | 25,502,836 | 0 | 25,502,836 | 0 | SCHEDULE 13D, 2026-06-16 |
| Xlife Sciences AG | 23,029,967 | 0 | 23,029,967 | 0 | SCHEDULE 13D, 2026-06-15 |
| European Molecular Biology Laboratory | 0 | 22,891,235 | 0 | 22,891,235 | SCHEDULE 13D, 2026-06-16 |
| Schoeni Gilbert Edgar | 22,539,749 | 0 | 22,539,749 | 0 | SCHEDULE 13D, 2026-06-15 |
| AQR Capital Management, LLC | 0 | 658,138 | 0 | 658,138 | SCHEDULE 13G/A, 2026-08-13 |
| AQR Capital Management Holdings, LLC | 0 | 658,138 | 0 | 658,138 | SCHEDULE 13G/A, 2026-08-13 |
| AQR Arbitrage, LLC | 0 | 658,138 | 0 | 658,138 | SCHEDULE 13G/A, 2026-08-13 |
The latest filing identifies Veraxa Biotech Holding AG f/k/a Voyager Acquisition Corp by CUSIP H9130A103 and gives its principal executive office as TALACKER 35, ZURICH (SCHEDULE 13G/A, 2026-08-13).
Source of funds (Item 3)
The source of the funding for the Common Shares acquired under the Merger Agreement is more fully described in Item 4 below.Deck David Lukas, SCHEDULE 13D, 2026-06-16
The source of the funding for the Common Shares acquired under the Merger Agreement is more fully described in Item 4 below.Xlife Sciences AG, SCHEDULE 13D, 2026-06-15
The source of the funding for the Common Shares acquired under the Merger Agreement is more fully described in Item 4 below.European Molecular Biology Laboratory, SCHEDULE 13D, 2026-06-16
The source of the funding for the Common Shares acquired under the Merger Agreement is more fully described in Item 4 below.Schoeni Gilbert Edgar, SCHEDULE 13D, 2026-06-15
Purpose of Transaction (Item 4)
Xlife Sciences AG
The Reporting Person acquired the PubCo Ordinary Shares reported herein in connection with the closing of the Business Combination as described in Item 3 above. The Reporting Person acquired the PubCo Ordinary Shares for investment purposes. Depending upon overall market conditions, other investment opportunities available to the Reporting Person, the Issuer's financial condition, results of operations, share price and other relevant factors, the Reporting Person may from time to time acquire additional PubCo Ordinary Shares, dispose of all or a portion of the PubCo Ordinary Shares beneficially owned by the Reporting Person, or take any other available courses of action (which may include, without limitation, any plans or proposals described in clauses (a)-(j) of Item 4 of Schedule 13D), in any case in one or more transactions. The Reporting Person does not have any present plans or proposals which relate to or would result in any of the actions specified in Item 4(a)-(j) of Schedule 13D, except as described below: As described in Item 6 below, the Reporting Person is party to that certain Voting, Support and Lock-Up Agreement among SPAC, the Company, and certain shareholders of the Company (the "Company Shareholder Support Agreement"), pursuant to which the Reporting Person agreed, among other things, not to transfer certain PubCo Ordinary Shares for a specified period following the Acquisition Closing, subject to certain exceptions. In addition, the Company Shareholders …The first part of Item 4 of the SCHEDULE 13D filed 2026-06-15; the filing has the rest
Schoeni Gilbert Edgar
The Reporting Person acquired the PubCo Ordinary Shares reported herein in connection with the closing of the Business Combination as described in Item 3 above. The Reporting Person acquired the PubCo Ordinary Shares for investment purposes. Depending upon overall market conditions, other investment opportunities available to the Reporting Person, the Issuer's financial condition, results of operations, share price and other relevant factors, the Reporting Person may from time to time acquire additional PubCo Ordinary Shares, dispose of all or a portion of the PubCo Ordinary Shares beneficially owned by the Reporting Person, or take any other available courses of action (which may include, without limitation, any plans or proposals described in clauses (a)-(j) of Item 4 of Schedule 13D), in any case in one or more transactions. The Reporting Person does not have any present plans or proposals which relate to or would result in any of the actions specified in Item 4(a)-(j) of Schedule 13D, except as described below: As described in Item 6 below, the Reporting Person is party to that certain Voting, Support and Lock-Up Agreement among SPAC, the Company, and certain shareholders of the Company (the "Company Shareholder Support Agreement"), pursuant to which the Reporting Person agreed, among other things, not to transfer certain PubCo Ordinary Shares for a specified period following the Acquisition Closing, subject to certain exceptions. In addition, the Company …The first part of Item 4 of the SCHEDULE 13D filed 2026-06-15; the filing has the rest
European Molecular Biology Laboratory
The Reporting Person acquired the PubCo Ordinary Shares reported herein in connection with the closing of the Business Combination as described in Item 3 above. The Reporting Person acquired the PubCo Ordinary Shares for investment purposes. Depending upon overall market conditions, other investment opportunities available to the Reporting Person, the Issuer's financial condition, results of operations, share price and other relevant factors, the Reporting Person may from time to time acquire additional PubCo Ordinary Shares, dispose of all or a portion of the PubCo Ordinary Shares beneficially owned by the Reporting Person, or take any other available courses of action (which may include, without limitation, any plans or proposals described in clauses (a)-(j) of Item 4 of Schedule 13D), in any case in one or more transactions. The Reporting Person does not have any present plans or proposals which relate to or would result in any of the actions specified in Item 4(a)-(j) of Schedule 13D, except as described below: As described in Item 6 below, the Reporting Person is party to that certain Voting, Support and Lock-Up Agreement among SPAC, the Company, and certain shareholders of the Company (the "Company Shareholder Support Agreement"), pursuant to which the Reporting Person agreed, among other things, not to transfer certain PubCo Ordinary Shares for a specified period following the Acquisition Closing, subject to certain exceptions. In addition, the Company …The first part of Item 4 of the SCHEDULE 13D filed 2026-06-16; the filing has the rest
Deck David Lukas
The Reporting Person acquired the PubCo Ordinary Shares reported herein in connection with the closing of the Business Combination as described in Item 3 above. The Reporting Person acquired the PubCo Ordinary Shares for investment purposes. Depending upon overall market conditions, other investment opportunities available to the Reporting Person, the Issuer's financial condition, results of operations, share price and other relevant factors, the Reporting Person may from time to time acquire additional PubCo Ordinary Shares, dispose of all or a portion of the PubCo Ordinary Shares beneficially owned by the Reporting Person, or take any other available courses of action (which may include, without limitation, any plans or proposals described in clauses (a)-(j) of Item 4 of Schedule 13D), in any case in one or more transactions. The Reporting Person does not have any present plans or proposals which relate to or would result in any of the actions specified in Item 4(a)-(j) of Schedule 13D, except as described below: As described in Item 6 below, the Reporting Person is party to that certain Voting, Support and Lock-Up Agreement among SPAC, the Company, and certain shareholders of the Company (the "Company Shareholder Support Agreement"), pursuant to which the Reporting Person agreed, among other things, not to transfer certain PubCo Ordinary Shares for a specified period following the Acquisition Closing, subject to certain exceptions. In addition, the Company …The first part of Item 4 of the SCHEDULE 13D filed 2026-06-16; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2026-06-15 | Xlife Sciences AG | 16.3% | SCHEDULE 13D |
| 2026-06-15 | Schoeni Gilbert Edgar | 15.9% | SCHEDULE 13D |
| 2026-06-16 | European Molecular Biology Laboratory | 16.2% | SCHEDULE 13D |
| 2026-06-16 | Deck David Lukas | 18% | SCHEDULE 13D |
| 2026-08-13 | AQR Capital Management, LLC | 0.46% | SCHEDULE 13G/A |
Questions about who owns Veraxa Biotech Holding AG f/k/a Voyager Acquisition Corp
Who owns Veraxa Biotech Holding AG f/k/a Voyager Acquisition Corp?
On this page, 4 holders' latest ownership filings report 5% or more of Veraxa Biotech Holding AG f/k/a Voyager Acquisition Corp: Deck David Lukas (18%, Schedule 13D, filed 2026-06-16), Xlife Sciences AG (16.3%, Schedule 13D, filed 2026-06-15), European Molecular Biology Laboratory (16.2%, Schedule 13D, filed 2026-06-16) and Schoeni Gilbert Edgar (15.9%, Schedule 13D, filed 2026-06-15).
Who are the largest shareholders of Veraxa Biotech Holding AG f/k/a Voyager Acquisition Corp?
By the share each holder's latest filing reports, the largest holders of Veraxa Biotech Holding AG f/k/a Voyager Acquisition Corp on this page are Deck David Lukas (18%), Xlife Sciences AG (16.3%) and European Molecular Biology Laboratory (16.2%).
When did Deck David Lukas buy into Veraxa Biotech Holding AG f/k/a Voyager Acquisition Corp?
The filings give report dates, not purchase dates. The earliest filing from Deck David Lukas on this page is the Schedule 13D, filed 2026-06-16, reporting 18%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 5 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for Veraxa Biotech Holding AG f/k/a Voyager Acquisition Corp. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.